ArticleAmerican journal of translational research2026
Effect of ropivacaine-dexamethasone combination on postpartum uterine pain, inflammation, and breastfeeding in multiparous women.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of epidural ropivacaine combined with dexamethasone on postpartum uterine cramping pain, inflammatory markers, and breastfeeding behavior in multiparous women.
methodsThis retrospective cohort study included 336 women who underwent vaginal delivery and received postpartum epidural analgesia between May 2022 and November 2024, including 211 multiparous women. The observation group (n = 172) received 0.15% ropivacaine combined with 10 mg dexamethasone, while the control group (n = 164) received only 0.15% ropivacaine. The severity of uterine cramping pain was assessed using the Visual Analogue Scale (VAS) at 2, 6, 12, 24, and 48 hours postpartum. Serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-10 (IL-10) were measured using ELISA, and C-reactive protein (CRP) was measured using a quantitative laboratory assay, at 6, 24, and 72 hours postpartum. Breastfeeding indicators and adverse events were recorded.
resultsThe VAS scores at all time points in the observation group were significantly lower than those of the control group (all P < 0.001), with a lower rescue analgesia rate (10.47% vs. 21.34%, P = 0.006). At 24 hours postpartum, the observation group showed significantly lower levels of TNF-α, IL-6, and CRP, and significantly higher levels of IL-10 (all P < 0.001); shorter first breastfeeding time (38.00 minutes vs. 52.00 minutes, P < 0.001); higher frequency of breastfeeding within 48 hours postpartum; and a higher rate of exclusive breastfeeding on day 7 postpartum (84.30% vs. 68.29%, P < 0.001). There were no significant differences in adverse events or neonatal outcome between the two groups (both P > 0.05).
conclusionsEpidural analgesia with ropivacaine combined with dexamethasone effectively alleviates postpartum uterine cramping pain in multiparous women, regulates the inflammatory responses, improves breastfeeding outcomes, and has a good safety profile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.